|
Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors Clinical research trials and Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors. Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors clinical trial. Human subjects often obtain the finest healthcare possible for their Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors  Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): Cancer Research Campaign Clinical Trials Centre ,
Synopsis: RATIONALE: Dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with solid tumors.
Details: OBJECTIVES: I. Determine the toxicity of dimethylxanthenone acetic acid (DMXAA) in patients with solid tumors. II. Establish a maximum tolerated dose for this drug in these patients. III. Determine the pharmacokinetics of DMXAA in these patients. IV. Determine the effect of this regimen on coagulation parameters, TNF and other cytokine production, nitric oxide, and serotonin production in these patients. V. Assess the efficacy of this drug in this patient population. VI. Determine the effect of this drug on tumor vasculature by evaluating any changes apparent on MRI scans in these patients. PROTOCOL OUTLINE: This is a dose escalation, multicenter study. Patients receive dimethylxanthenone acetic acid (DMXAA) IV over 20 minutes once weekly for 6 weeks, followed by 2 weeks of rest. An additional course of therapy may be administered in the absence of unacceptable toxicity or disease progression. Cohorts of 3 patients receive escalated doses of DMXAA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose limiting toxicity. PROJECTED ACCRUAL: A minimum of 3 patients will be accrued to each dose level used to determine the maximum tolerated dose.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/75 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed solid tumor that is not amenable to any standard therapy or is refractory to conventional therapy; Tumor mass larger than 3 cm accessible to MRI scan - Documented progression within the past 2 months --Prior/Concurrent Therapy-- - At least 4 weeks since prior anticancer therapy (6 weeks for nitrosoureas and mitomycin) and recovered --Patient Characteristics-- - Age: 18 to 75 - Performance status: WHO 0-2 - Life expectancy: Greater than 3 months - Hematopoietic: Hemoglobin at least 9 g/dL; WBC at least 3,000/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin less than 1.2 mg/dL; ALT less than 2 times upper limit of normal (ULN); Alkaline phosphatase less than 2 times ULN - Renal: Creatinine less than 1.5 mg/dL - Other: Fertile patients must use effective contraception; No concurrent malignancy except cone biopsied carcinoma in situ of the cervix and adequately treated basal or squamous cell carcinoma of the skin; No other serious medical condition; No uncontrolled infection or serious infection within the past 28 days; Must live within 1 hour of Mount Vernon Hospital, UK
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GordonSampson Rustin, Study Chair, Cancer Research Campaign Clinical Trials Centre
Mount Vernon Hospital
Northwood, England, HA6 2RN
United Kingdom
Additional Information:
Study ID Numbers: CDR0000066804; CRC-PHASE-I/II-PH1/048,EU-98065
Study Start Date: October 1995
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003697
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
2. Darbepoetin alfa in Treating Anemia in Patients With Cancer Who Are Receiving Chemotherapy
3. XK469 in Treating Patients With Advanced Solid Tumors
4. Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain
5. Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other England Clinical Trials
Other Northwood Clinical Trials
Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
|
|
|
|
|
|
|
|
